Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.

Abstract: A production cell includes: at least one robot arranged to handle products; at least one buffer area for intermediate storage of products inside the production cell; a vision system with cameras arranged to determine, based on images from the cameras, the identity and the location of objects in the production cell a plurality of production modules, each production module comprising at least one Hardware Module configured to process products; and a plurality of module attachment locations, each module attachment location being configured to connect with an interface section of a production module through at least a physical connection and a power connection.

Abstract: A robotic system includes at least two Hardware Modules, each having at least one sensor for measuring an internal property, a communication unit, a data storage unit and an embedded controller. The embedded controller is configured to collect collected data including status data representing the current status of the Hardware Module; and operating data representing usage of the Hardware Module. At least part of the collected data is determined from sensor data, and the embedded controller is configured to store or transmit the collected data. The robotic system including a central computation and command unit configured to receive the collected data; and to control operation of the robotic system by controlling operation of at least one actuator of the at least two Hardware Modules.

Abstract: A robotic system includes at least two Hardware Modules, each having at least one sensor for measuring an internal property, a communication unit, a data storage unit and an embedded controller. The embedded controller is configured to collect collected data including status data representing the current status of the Hardware Module; and operating data representing usage of the Hardware Module. At least part of the collected data is determined from sensor data, and the embedded controller is configured to store or transmit the collected data. The robotic system including a central computation and command unit configured to receive the collected data; and to control operation of the robotic system by controlling operation of at least one actuator of the at least two Hardware Modules.

Abstract: A production cell includes: at least one robot arranged to handle products; at least one buffer area for intermediate storage of products inside the production cell; a vision system with cameras arranged to determine, based on images from the cameras, the identity and the location of objects in the production cell a plurality of production modules, each production module comprising at least one Hardware Module configured to process products; and a plurality of module attachment locations, each module attachment location being configured to connect with an interface section of a production module through at least a physical connection and a power connection.

Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.

Abstract: The present invention relates to antibodies or fragments thereof binding to human WT1/HLA. In particular, the present invention relates to antibodies or fragments thereof that have combined improved and/or beneficial properties, and are therefore suited for clinical development.

Abstract: A robotic system includes at least two Hardware Modules, each having at least one sensor for measuring an internal property, a communication unit, a data storage unit and an embedded controller. The embedded controller is configured to collect collected data including status data representing the current status of the Hardware Module; and operating data representing usage of the Hardware Module. At least part of the collected data is determined from sensor data, and the embedded controller is configured to store or transmit the collected data. The robotic system including a central computation and command unit configured to receive the collected data; and to control operation of the robotic system by controlling operation of at least one actuator of the at least two Hardware Modules.

Abstract: The present invention relates to antibodies or fragments thereof binding to human WT1/HLA. In particular, the present invention relates to antibodies or fragments thereof that have combined improved and/or beneficial properties, and are therefore suited for clinical development.

Abstract: Monoclonal antibodies that act as potentiators, stimulators and agonists of guanylyl cyclase receptors are disclosed.

Abstract: This disclosure generally relates to antibodies or fragments thereof which interact with the bacterial protein MprF. The disclosure further discloses antibodies, which bind to specific extracellular motifs of MprF. The disclosure further relates to therapeutics comprising MprF-specific antibodies and methods of treatment using MprF-specific antibodies or fragments thereof.